SEAGEN INC.
NASDAQ: SGEN
▼
175.60
-2.73
-1.53%
1 Day
-
Open
177.20
-
Previous Close
178.33
-
Volume (Avg)
642.22k (1.09M)
-
Day's Range
175.10-178.38
-
52Wk Range
105.43-192.79
-
Market Cap.
32.39B
-
Dividend Rate ( Yield)
-
-
Beta
-
-
Shares Outstanding
-
-
P/E Ratio (EPS)
53.58 (-)
Top Stories
-
Recap: Seagen Q2 Earnings
Benzinga 7/28/2022 -
Timeline: The rise and fall of Washington’s highest-paid CEO
Seattle Times -
Seattle Genetics's Return On Capital Employed Overview
Benzinga -
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates
Nasdaq -
Seattle Genetics: Q2 Earnings Snapshot
News Tribune 7/30/2022Seattle Genetics expects full-year revenue in the range of $1.71 billion to $1.8 billion. This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks sto
-
Clay Siegall built Seattle biotech firm Seagen into a $1.6B giant. Then the cops came calling
Seattle Times -
Seagen Inc. (NASDAQ:SGEN) Holdings Lifted by Envestnet Asset Management Inc.
Defense World -
Seagen Inc.: Narrow-Moat Seagen Reports Strong Q2 Results in Line With Expectations; Maintaining $150 FVE
YAHOO!Finance -
StockNews.com Upgrades Seagen (NASDAQ:SGEN) to “Buy”
Defense World -
Benefits of pre-surgical immunotherapy were independent of race in patients with aggressive breast cancer
EurekAlert! -
Global Next Generation Biological Drugs Market Size Worth USD 15 Billion By 2027 | CAGR 20%: Infinium Global Research
MarketWatch -
Monoclonal Mouse Antibody Market Size To Rise At 5.4% CAGR Through 2027
Middle East North Africa Financial Network -
Seagen With And Without A Merck Buyout
Seeking Alpha -
Seagen's (SGEN) Earnings & Revenues Surpass Estimates in Q2
Nasdaq -
Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors
Associated Press 7/26/2022Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Dr.
-
Drug, Biotech Stocks' Q2 Earnings on Jul 28: MRK, PFE & More
YAHOO!Finance
